UPA Magtidelira 33 Research Compound Hybrid Peptide Pen - 33mg

Weight Management • Appetite Control • Metabolic Support

MAGTIDLIRA 33 is a revolutionary dual-action injectable designed for effective weight management and metabolic optimization. Combining Semaglutide (3 mg) and Tirzepatide (30 mg), this innovative formula offers unmatched performance in appetite control, fat reduction, and sustained energy levels—all delivered in a convenient weekly injection.

Key Benefits

• Superior Appetite Suppression: Enhances feelings of fullness and significantly reduces cravings, making it easier to adhere to dietary changes.
• Accelerated Fat Loss: Promotes effective fat reduction while preserving lean muscle mass, helping to maintain body composition.
• Improved Glucose Control: Optimizes metabolic efficiency by enhancing glucose management, which is crucial for overall health.

Disclaimer

This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPRA) for human or animal use.

Not for human consumption or medical use. Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.